文献速递复苏、休克与脓毒症创伤与烧伤

新鲜冰冻血浆减轻长时间低血压复苏模型中的肺损伤

Fresh frozen plasma attenuates lung injury in a novel model of prolonged hypotensive resuscitation.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论小鼠长时间低血压复苏模型中,新鲜冰冻血浆较Hextend减轻肺组织病理损伤、炎症和通透性,并恢复肺syndecan-1。

本研究建立小鼠长时间低血压复苏(PHR)模型:开腹后失血性休克(平均动脉压35±5 mmHg持续90分钟),随后6小时内用新鲜冰冻血浆(FFP)或Hextend复苏维持平均动脉压55-60 mmHg。结果显示FFP组肺组织病理损伤评分4.38±2.07 vs Hextend组7.5±0.93(0-9分,p=0.002),与假手术组4.0±1.93相当(p=0.99);FFP还降低肺髓过氧化物酶相对荧光(0.116±0.044 vs 0.308±0.054,p=0.002)、恢复肺syndecan-1相对荧光(0.514±0.061 vs 0.059±0.021,p<0.001)并减轻肺高通透性(Evans蓝7.30±1.34 μg vs 14.91±5.55 μg/100 mg肺组织,p=0.005)。作者认为该模型支持在前方环境中进一步开发和应用基于血浆的复苏策略。

要点

  • 小鼠PHR模型中,FFP组肺组织病理损伤评分4.38±2.07 vs Hextend组7.5±0.93(0-9分,p=0.002),与假手术组4.0±1.93相当(p=0.99)。
  • FFP组肺髓过氧化物酶相对荧光0.116±0.044 vs Hextend组0.308±0.054(p=0.002),提示FFP减轻肺炎症。
  • FFP组肺syndecan-1相对荧光0.514±0.061 vs Hextend组0.059±0.021(p<0.001),提示FFP恢复内皮细胞完整性标志物。
  • FFP组Evans蓝7.30±1.34 μg/100 mg肺组织 vs Hextend组14.91±5.55 μg/100 mg肺组织(p=0.005),提示FFP减轻肺高通透性。
  • 作者认为该模型支持在前方环境中进一步开发和应用基于血浆的复苏策略。

适用人群与场景

  • 小鼠失血性休克模型:开腹后平均动脉压35±5 mmHg持续90分钟,随后接受长时间低血压复苏维持平均动脉压55-60 mmHg共6小时。
  • 假手术组仅接受置管。

诊断标准与关键阈值

  • 失血性休克定义:平均动脉压35±5 mmHg持续90分钟。
  • 长时间低血压复苏目标:平均动脉压55-60 mmHg维持6小时。

处置流程与药物剂量

  • 失血性休克后分别用新鲜冰冻血浆(FFP)或Hextend复苏,维持平均动脉压55-60 mmHg共6小时。
  • 6小时后处死动物,取肺组织用苏木精-伊红染色、髓过氧化物酶免疫荧光染色和Evans蓝检测组织病理损伤、炎症和通透性,并评估肺syndecan-1免疫染色作为内皮细胞完整性指标。

研究设计与关键结果

  • 研究类型:基础科学(动物实验),小鼠长时间低血压复苏模型。
  • 所有FFP、Hextend和假手术组动物均存活至复苏结束。
  • 肺组织病理损伤评分(0-9分):FFP组4.38±2.07 vs Hextend组7.5±0.93,p=0.002;FFP组与假手术组4.0±1.93相比p=0.99。
  • 肺髓过氧化物酶相对荧光:FFP组0.116±0.044 vs Hextend组0.308±0.054,p=0.002。
  • 肺syndecan-1相对荧光:FFP组0.514±0.061 vs Hextend组0.059±0.021,p<0.001。
  • 肺Evans蓝渗出:FFP组7.30±1.34 μg/100 mg肺组织 vs Hextend组14.91±5.55 μg/100 mg肺组织,p=0.005。

证据类型、等级与局限

  • 证据类型:基础科学(动物实验)。
  • 证据等级:原文标注Level of Evidence: Basic science。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该模型支持在前方环境中进一步开发和应用基于血浆的复苏策略。
  • 原文未据此给出临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhagic shock remains a leading cause of early death among severely injured in both civilian and military settings. As future military operations will require strategies allowing prolonged field care of the injured, we sought to develop an in vivo model of prolonged hypotensive resuscitation (PHR) and to evaluate the role of plasma-based resuscitation in this model. We hypothesized that resuscitation with fresh frozen plasma (FFP) would mitigate lung injury when compared with Hextend in a rodent model of PHR.

METHODS: Mice underwent laparotomy and hemorrhagic shock (mean arterial blood pressure, 35 ± 5 mm Hg × 90 minutes) followed by PHR with either FFP or Hextend to maintain a mean arterial blood pressure of 55 mm Hg to 60 mm Hg for 6 hours. Sham animals underwent cannulation only. At the end of 6 hours, animals were euthanized, and lung tissue harvested for measurement of histopathologic injury, inflammation and permeability using hematoxylin and eosin staining, myeloperoxidase immunofluorescence staining and Evans Blue dye. Pulmonary syndecan-1 immunostaining was assessed as an indicator of endothelial cell integrity.

RESULTS: All animals in the FFP, Hextend, and sham groups survived to the end of resuscitation. Resuscitation with FFP mitigated lung histopathologic injury compared with Hextend (histologic injury score of 4.38 ± 2.07 vs. 7.5 ± 0.93, scale of 0-9, p = 0.002) and was comparable to shams (histologic injury score of 4.0 ± 1.93, scale of 0-9, p = 0.99). Fresh frozen plasma also reduced lung inflammation (0.116 ± 0.044 vs. 0.308 ± 0.054 relative fluorescence of myeloperoxidase, p = 0.002) and restored pulmonary syndecan-1 (0.514 ± 0.061 vs. 0.059 ± 0.021, relative syndecan-1 fluorescence, p < 0.001) when compared with Hextend. Consistently, FFP mitigated lung hyperpermeability compared with Hextend (7.30 ± 1.34 μg vs. 14.91 ± 5.55 μg Evans blue/100 mg lung tissue, p = 0.005).

CONCLUSION: We have presented a novel model of PHR of military relevance to the prolonged field care environment. In this model, FFP maintains its pulmonary protective effects using a PHR strategy compared with Hextend, which supports the need for further development and implementation of plasma-based resuscitation in the forward environment.

LEVEL OF EVIDENCE: Basic science.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Chipman AM, Wu F, Pati S, et al. Fresh frozen plasma attenuates lung injury in a novel model of prolonged hypotensive resuscitation. J Trauma Acute Care Surg. 2020. PMID: 32282752. doi:10.1097/TA.0000000000002719

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。